Clinical Trials on Hairy Cell Leukemia in United Kingdom

Total 19768 results

Cambridge Antibody Technology

Unknown

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Leukemia | Hairy Cell Leukemia | HCL

United States, Poland, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
National Cancer Institute (NCI)

Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Terminated

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
MedImmune LLC
Cambridge Antibody Technology

Completed

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Hairy Cell Leukemia

United States, Poland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaborators

Active, not recruiting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Memorial Sloan Kettering Cancer Center
Yale University; Dana-Farber Cancer Institute

Active, not recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Leukemia | Leukemia, Hairy Cell | Hairy Cell Leukemia

United States
Scripps Health

Recruiting

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

LMB-2 to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
MedImmune LLC

Completed

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Leukemia, Hairy Cell

Italy, Spain, United States, Belgium, Poland, Czechia, Germany, Serbia, United Kingdom, France, Israel, Ireland, Canada, Norway
MedImmune LLC

Completed

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Leukemia

United States
King's College Hospital NHS Trust

Completed

Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

United Kingdom
Ohio State University Comprehensive Cancer Center
Hairy Cell Leukemia Foundation

Recruiting

Hairy Cell Leukemia Patient Data Registry (HCL-PDR)

Leukemia, Other

United States
King's College Hospital NHS Trust

Completed

CLL Empirical Antibiotic Regimen (CLEAR)

Chronic Lymphocytic Leukaemia (CLL)

United Kingdom
Northwestern University
National Cancer Institute (NCI)

Completed

Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia

Leukemia

United States
AstraZeneca
Iqvia Pty Ltd

Terminated

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL) | Hairy Cell Leukemia (HCL) | Cutaneous T Cell Lymphoma (CTCL) | Non-Hodgkins Lymphoma (NHL) | Adult T Cell Lymphoma (ATL)

United States
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust; University Hospital Plymouth...

Unknown

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib (CLARITY)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukaemia

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
Medical Research Council; UCL Great Ormond Street Institute of Child Health

Recruiting

Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (TvT CAR7)

Relapsed/Refractory T-cell Acute Lymphoid Leukaemia

United Kingdom
GlaxoSmithKline

Completed

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients (BIFROST)

Leukaemia, Lymphocytic, Chronic

United States, United Kingdom
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLL

United States
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom
National Cancer Institute (NCI)

Completed

Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia

Leukemia

United States
Alexey Danilov, MD
Gilead Sciences; Oregon Health and Science University

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Anemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditions

United States
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States
The Christie NHS Foundation Trust
Celgene Corporation; Leukemia Research Fund

Terminated

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

Chronic Lymphocytic Leukaemia

United Kingdom
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
National Cancer Institute (NCI)

Terminated

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
AstraZeneca

Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

United Kingdom
Cancer Research UK

Completed

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

Chronic Lymphocytic Leukaemia | Indolent B-cell Lymphoma | Waldenström Macroglobulinaemia

United Kingdom
University College, London
Bloodwise

Active, not recruiting

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT Indicated

United Kingdom
Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Great Ormond Street Hospital for Children NHS Foundation...
Wellcome Trust

Recruiting

Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (CARAML)

Relapsed Acute Myeloid Leukaemia

United Kingdom
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Juvenile Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Lymphoblastic Leukemia | Prolymphocytic Leukemia | Hairy Cell Leukemia | Acute Undifferentiated Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Childhood Acute Myeloid... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Onxeo

Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

B-cell Chronic Lymphocytic Leukemia

United Kingdom

Clinical Trials on Hairy Cell Leukemia in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations